Respiratory Tract Diseases Clinical Trial
— ASC COVID-19Official title:
Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study
Verified date | May 2020 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The emerging field of stem cell therapy holds promise of treating a variety of diseases.
Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have
proven their potential for regenerative therapy in patients with ischemic heart disease. Both
of these cell types have putative immunomodulatory properties, as they have demonstrated
their ability to evade recognition and actively suppress the immune system.
This knowledge is transferred into studies with COVID-19 patients having severe pulmonary
dysfunction, to modify the virus induced immunological and inflammatory activity involved in
the progression of disease often leading to prolonged ICU stay and in some occasion's death.
We will conduct a clinical trial in which patients with COVID-19 and severe pulmonary
symptoms will be randomized to either placebo or treatment with allogeneic CSCC_ASCs from
adipose tissue. The aim is to assess the impact of CSCC_ASCs on the activated immune system
and clinical efficacy on pulmonary function.
The perspective is that this new information can be of pivotal importance and potentially be
a paradigm shift for the clinical problems and severe outcome seen in some patients with
severe COVID-19 and other severe diseases with Acute Respiratory Distress Syndrome.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 30, 2021 |
Est. primary completion date | January 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients between 18-80 years - Confirmed HCoV-19 infection - Temperature above 38.0o C - Pulmonary symptoms and signs, at least one of the following before clinical decision for intubation and respirator treatment: 1. Respiratory distress, RR = 30/min; 2. Oxygen saturation = 93% at rest state; 3. Arterial partial pressure of oxygen (PaO2) / Fraction of inspiration O2 (FiO2) = 300mmHg, 1mmHg=0.133kPa - Pneumonia that is judged by chest radiograph or computed tomography - In respirator and possible for treatment within the first 24 hours Exclusion Criteria: - Patients that have need for additional immunosuppressive treatment - Patients with any past (within the past 3-5 years) or present malignancy (other than excised basal cell carcinoma). - Co-Infection with other infectious agent. - Females capable of becoming pregnant must have a negative pregnancy test prior to treatment. After inclusion, they must use contraceptives for 2 months following the given stem cell treatment. The pill, spiral, depot injection of progesterone, sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe contraceptives. - Patients who are participating in other clinical trials. |
Country | Name | City | State |
---|---|---|---|
Denmark | 2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in clinical critical treatment index | day 7 from randomization | ||
Secondary | Days of respirator treatment | 3 months | ||
Secondary | Improvement of clinical symptoms including duration of fever and respiratory need | 3 months | ||
Secondary | Mortality | 3 months | ||
Secondary | Marker of Immunological function -CD4+ and CD8+ T cell count | 3 months | ||
Secondary | C-reactive protein and leucocyte | 3 months | ||
Secondary | Cytokine profile | 3 months | ||
Secondary | Glomerular Filtration Rate | 3 months | ||
Secondary | Duration of hospitalization | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Withdrawn |
NCT04842331 -
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
|
Phase 2/Phase 3 | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT00382408 -
A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001
|
Phase 3 | |
Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT05907564 -
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
|
N/A | |
Not yet recruiting |
NCT05534685 -
Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia
|
N/A | |
Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT05056766 -
How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
|
||
Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05565872 -
Effects of Supervision During a Community-based Exercise Intervention (Urban Training) in Patients With COPD
|
N/A | |
Not yet recruiting |
NCT05592431 -
Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Neonates
|
N/A | |
Completed |
NCT03401463 -
Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar
|
N/A | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Active, not recruiting |
NCT01055990 -
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
|
Phase 2 | |
Completed |
NCT00743990 -
Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough
|
N/A | |
Completed |
NCT02198391 -
Study of Echinaforce Junior Tablets in Children With Acute Colds
|